"The US Food and Drug Administration (FDA) has approved a fixed-dose combination of memantine hydrochloride extended-release (XR) and donepezil hydrochloride (Namzaric, Actavis plc/Adamas Pharm) for moderate to severe Alzheimer's-related de"...
Mechanism Of Action
Flutemetamol F 18 binds to β-amyloid plaques in the brain and the F-18 isotope produces a positron signal that is detected by a PET scanner. In in vitro binding studies using postmortem human brain homogenates containing fibrillar β-amyloid, the dissociation constant (K d) for flutemetamol was 6.7 nM.
Selectivity of [3H]flutemetamol binding in post-mortem human brain sections was demonstrated using autoradiography, silver-stained protein, and immunohistochemistry (monoclonal antibody to β-amyloid) correlation studies.
Following intravenous injection, flutemetamol F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain flutemetamol F 18 content, with differential retention of the drug in cortical areas that contain β-amyloid aggregates compared to areas that lack the aggregates. The time-activity curves for flutemetamol F 18 in the brain of subjects with positive scans shows continual signal increases from time zero through 30 minutes post administration, with stable values thereafter up to at least 120 minutes post-injection. Differences in signal intensity between brain regions that specifically retain flutemetamol F 18 and brain regions with nonspecific retention of the drug form the basis of image interpretation methods [see DOSAGE AND ADMINISTRATION].
The test-retest distribution of flutemetamol F 18 was evaluated in 5 subjects with probable AD who underwent two administrations of flutemetamol F 18 (followed by PET scans) separated by a time period of 1 to 4 weeks. Images were reproducible when evaluated semi-quantitatively using an automated assessment of SUV in pre-specified cortical regions of brain.
Following intravenous injection of 185 MBq (5 mCi) of Vizamyl in humans, flutemetamol F 18 plasma concentrations declined by approximately 75% in the first 20 minutes post-injection, and by approximately 90% in the first 180 minutes. The F 18 in circulation during the 30-120 minutes imaging window in plasma was principally associated with flutemetamol metabolites. Excretion was approximately 37% renal (28-45%; n=6) and 52% hepatobiliary (40-65%; n=6).
Vizamyl was evaluated in two clinical studies (Study One and Study Two) in adult subjects with a range of cognitive function, including some terminally ill patients who had agreed to participate in a post-mortem brain donation program. Both studies were single-arm and subjects underwent Vizamyl injection and scan. The images were interpreted by five independent readers masked to all clinical information; readers in Study Two were na´ve to all forms of amyloid PET imaging. PET images were reviewed first without, and subsequently with, brain CT or MRI images.
Study One evaluated pre-mortem Vizamyl PET images from terminally ill patients and compared the results to postmortem truth standard assessments of cerebral cortical neuritic plaque density in patients who died during the study. Readers evaluated images using a clinically applicable binary image interpretation method (positive/negative) that involved evaluating regional Vizamyl brain uptake to yield a final overall image assessment that was compared to the truth standard. Before image interpretation, all readers underwent in-person tutoring on image interpretation. To determine the agreement between the in vivo Vizamyl image results and the post-mortem whole brain amyloid neuritic plaque density, Vizamyl results (negative/positive) were pre-specified to correspond with specific global histopathology plaque density scores, based upon a modification of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria (Table 5), which use neuritic plaque counts as a necessary pathological feature of AD. Plaques were counted on microscope slides with modified Bielschowsky silver-stained tissue sections. The global brain neuritic plaque density score for each subject was determined by averaging across the scores (0-3) for five grey matter fields per slide and then across the six slides for each of eight regions; if any one region had a regional score of greater than 1.5, the subject's brain was classified as positive for amyloid.
Table 5: Global and Regional Neuritic Plaque Score
Correlates to Vizamyl Image Results
|Vizamyl Image Result||CERAD Classification (Score)||Neuritic Plaque Counts|
|Sparse (1)||1 to 5|
|Positive||Moderate (2)||6 to 19|
|Frequent (3)||> 20|
In Study One, one hundred eighty patients were dosed with Vizamyl and 176 were imaged. The median patient age was 82 years (range 47 to 98 years) and 57% of the patients were female. By medical history 44 patients had no cognitive impairment, 135 had dementia, no patients had mild cognitive impairment (MCI), and one patient had memory loss of unspecified nature. Sixty-nine patients died during the study; 68 had cerebral cortical amyloid status determined (43 positive and 25 negative) and were included in the primary analysis. The time interval between the Vizamyl scan and death ranged from 0 to 13 months, with a median of 2.6 months, and was less than one year for 66 patients and between 12 to 13 months for 2 patients. At autopsy, the global brain neuritic plaque density category (CERAD classification as in Table 5) was available for 67/68 subjects: frequent (n = 19); moderate (n = 22); sparse (n = 14); and none (n = 12).
In Study Two, the effectiveness of an electronic training program for Vizamyl image orientation and interpretation was evaluated using Vizamyl PET images from across subjects with different cognitive abilities who had participated in earlier studies. Inter-reader reproducibility of image interpretation was assessed using images from subjects with a truth standard (68 patients who underwent an autopsy and 36 known or suspected normal pressure hydrocephalus patients with in vivo brain biopsy) and without a truth standard (28 cognitively normal volunteers 55 years or above, 80 patients with amnestic mild cognitive impairment (aMCI), 33 patients with probable AD (pAD)), and 31 young healthy volunteers. Additionally, intra-reader reproducibility was assessed from 29 images (10%). Among the 276 subjects, the median age was 72 years (range 20 to 95), 136 were females, and 251 were Caucasian.
Vizamyl performance characteristics for Study One and Study Two patients with an autopsy-based truth standard are shown in Table 6 and Table 7. Among patients who underwent autopsy (n=68; 43 positive and 25 negative based on histopathology), the median (and range) of correct read results, false negatives, and false positives were 59 (51, 61), 5 (3, 8), 3 (2, 14), respectively, for in-person training (Study One); and were 60 (55 to 61), 3 (3 to 6), 4 (2 to 10), respectively, for electronic media training (Study Two). Image reproducibility for various subject groups in Study Two is presented in Table 8. Inter-reader reproducibility analysis showed an overall Fleiss' kappa statistic of 0.83 (95% CI 0.79 to 0.86) which met the pre-specified success criterion (95% CI lower bound > 0.60). Intra-reader reproducibility analysis showed that, between the two readings for each of the 29 duplicate patient images, one of the five readers had complete agreement for all 29 images, two readers had discordant reads for a single image, and two readers had discordant reads for two images. Intra-reader reproducibility for a subgroup of 8 images from aMCI patients showed that all five readers had complete agreement for all duplicate images.
Table 6: Vizamyl Scan
Results by Reader Training Method among Patients with Autopsy (n = 68)
|Test Performance||In-Person Training (Study One)||Electronic Media Training (Study Two)|
|Range among the 5 readers||81 -93||86 -93|
|Range among the 5 readers||44 -92||60 -92|
Table 7: Vizamyl Scan
Interpretations by Reader Training Method among Autopsied Patients (n = 68)
|In-Person Training (Study One)||Electronic Media Training (Study Two)|
|All scans with autopsies (n = 68a)||Correct||57||60||51||59||61||58||61||61||55||60|
|a43 positive and 25 negative based on histopathology|
Table 8 : (Study Two): Median Number of Positive
Vizamyl Scans and Reproducibility of Scan Results
|Subject Group by Cognitive and Truth Standard
|Positive Scans Na||Kappa
|Percent of Scans with Inter-reader Agreement|
|3 of 5 readers agreed||4 of 5 readers agreed||5 of 5 readers agreed|
|All 276 subjects||139||0.83
|All subjects with a TS, n=104
(68 autopsy; 36 biopsy)
|All subjects without a TS, n = 172||76||0.88
|pAD, n = 63
(30 with TSb; 33 no TS)
|aMCI, n = 80
(0 with TS)
|Elderly cognitively normal without TS, n = 28||2||0.46
|Cognitively normal with TSc,
(non-AD) dementia with TS, .~d n=53
|aShown is the median number of scans interpreted as positive
across the 5 readers for each subgroup of subjects listed in the first column.
b30 with TS from autopsy
c21 with TS from autopsy, 0 with TS from biopsy
d17 from autopsy, 5 of 36 with TS from biopsy were not definitively classified as pAD based on clinical diagnosis pAD: probable AD; aMCI: amnestic MCI; Elderly: 55 years or above
Last reviewed on RxList: 12/18/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Vizamyl Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.